Evaluation of Anticoagulants among Venous Thromboembolism Patients with Active Cancer: Pooled Analysis from Claims Databases

Study identification

• EU PAS number:
  EUPAS25308
• Study ID:
  49163
• Official title and acronym:
  Evaluation of Anticoagulants among Venous Thromboembolism Patients with Active Cancer: Pooled Analysis from Claims Databases
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This study will evaluate patient characteristics and the use of apixaban, warfarin, and LMWH use among VTE patients with active cancer.
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Planned:01/03/2018

Actual:20/03/2018

Study start date

Planned:21/08/2018

Actual:21/10/2018

Data analysis start date

Planned:31/08/2018

Actual:21/10/2018

Date of final study report

Planned:30/11/2023

Actual:27/10/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer/BMS

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable